Abstract 459P
Background
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death among males and females. There is evidence that diet habit may influence lung cancer risk. To determine the association between fish intake and dietary polyunsaturated fatty acids (PUFA) and incidence of lung cancer, we identified all available studies to clarify the dose-response relationship between fish and PUFA and lung cancer risk, evaluated the potential effects of frequent fish and PUFA intake on lung cancer mortality, and studied the ability of their supplementations during chemotherapy in patients with lung cancer.
Methods
We systematically reviewed and meta-analyzed the published studies in MEDLINE, EMBASE databases, Cochrane Library database (Cochrane central register of controlled trials) and ClinicalTrials, supplemented with manual screening. Large-scale prospective cohort study and randomized control trials quantifying the associations of fish and PUFA consumption with risk of lung cancer were included. Two investigators dependently assessed studies for inclusion and extracted data on methods, interventions, outcomes and study quality. Relative risk (RR) with 95% confidence interval (CI) was calculated.
Results
13 population-based prospective cohort studies involving 1,785,000 participants and 2 randomized control trials were included. Our study demonstrated that dietary PUFA significant reduced risk of lung cancer for men (RR 0.99, 95%CI 0.98 to 1.00) and USA population (RR 0.99, 95%CI 0.98 to 1.00). Dose-response analysis indicated that a 5g/day increment of dietary PUFA was associated with 5% lower risk of lung cancer (RR 0.95, 95%CI 0.91 to 0.99). In addition, PUFA supplementation is significant improved overall survival in patients with lung cancer (RR 1.98, 95%CI 1.09 to 3.59).
Conclusions
Our study showed an inverse association between dietary PUFA and risk of lung cancer in males and among USA population. Although smoking cessation is the single biggest factor associated with lung cancer risk reduction, this study adds to a growing body of evidence that diet may have a role in modestly reducing lung cancer risk.
Clinical trial identification
Editorial acknowledgement
This work was supported by program for the National Natural Science Foundation of China (grant number 81700025), the Medical and Health Science and Technology Project of Zhejiang (grant number 2018245859), the Medical Science and Technology Plan Projects of Ningbo (grant number 2016A03), the Science Foundation of Zhejiang (grant number LY15H010002) and the Beijing Medical Health Foundation (grant number YWJKJJHKYJJ-HX32).
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract